Niedokarboksylowane białko macierzy Gla u pacjentów z zawałem serca z uniesieniem odcinka ST oraz przewlekłymi zespołami wieńcowymi by Konduracka, Ewa et al.
84 www.journals.viamedica.pl/folia_cardiologica
Folia Cardiologica 2021 
vol. 16, no. 2, pages 84–90 
DOI: 10.5603/FC.a2020.0047 




Address for correspondence: Ewa Konduracka MD, PhD, Uniwersytet Jagielloński, Collegium Medicum, Klinika Choroby Wieńcowej i Niewydolności Serca, 
Szpital Jana Pawła II, ul. Prądnicka 80, 31–202 Kraków, Poland, phone: +48 12 614 22 18, e-mail: ekonduracka@interia.eu
This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download 
articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
Undercarboxylated matrix Gla protein in patients  
with ST-segment elevation myocardial infarction  
and chronic coronary syndromes
Niedokarboksylowane białko macierzy Gla u pacjentów z zawałem serca  
z uniesieniem odcinka ST oraz przewlekłymi zespołami wieńcowymi
Ewa Konduracka1, 2, Marcin Pawłowski1, Danuta Fedak3, Grzegorz Gajos1, 2,  
Aleksander Siniarski1, 2●iD, Paweł Rostoff1, 2, Marta Węgrzynowska1, 2, Jadwiga Nessler1, 2
1Department of Coronary Disease and Heart Failure, Jagiellonian University Medical College, Kraków, Poland 
2John Paul II Hospital, Kraków, Poland 
3Department of Clinical Biochemistry, Jagiellonian University Medical College, Kraków, Poland
Abstract
Introduction. Matrix Gla proteins (MGPs) are usually considered as natural inhibitors of soft tissue calcification in chronic 
inflammatory disorders. However, MGP levels in acute inflammation related to myocardial ischemia have been poorly 
investigated.
This study aimed to compare the serum concentrations of uncarboxylated MGPs (ucMGPs) between patients with 
ST-segment elevation myocardial infarction (STEMI) vs. with chronic coronary syndromes (CCS) and to investigate the 
association between ucMGP concentration and an increased risk of major adverse cardiovascular events (MACE) in 
STEMI patients.
Material and methods. 155 consecutive patients were enrolled (mean ± standard deviation age, 64 ± 13 years), includ-
ing 80 patients with a first STEMI and 75 ones with CCS as controls. Blood samples were obtained within the first 24 h 
from hospital admission to evaluate ucMGP levels. Combination of MACE [all-cause mortality, heart failure (HF) within 
the first 30 days after myocardial infarction] was evaluated.
Results. ucMGP levels were higher in patients with STEMI than in controls (2929 ± 96.5 ng/mL vs. 67.3 + 32.3 ng/mL; 
p < 0.0001). A significant positive correlation between ucMGP and high-sensitivity C-reactive protein, troponin levels 
was found.
Multivariate analysis showed that ucMGP was an independent associate of STEMI [odds ratio (OR) 1.39; confidence 
interval (CI): 0.78–2.14, p = 0.01]. Although ucMGP did not predict the combined MACE, however it was an independent 
associate of HF occurrence 30 days after STEMI (OR, 1.20; 95% CI: 1.07–1.30, p = 0.04).
Conclusion. Elevated ucMGP levels in patients with STEMI indicate that some MGPs may be involved in disorders related 
not only to chronic but also acute inflammatory states.
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Material and methods
Study population
We enrolled 155 consecutive patients, including patients 
with the diagnosis of a first STEMI (N = 80) and patients 
with CCS (N = 75) who served as controls. All participants 
were hospitalized at the Department of Coronary Disease 
and Heart Failure at Jagiellonian University Medical Col-
lege in Kraków, Poland. After coronary angiography, all 
participants were referred for percutaneous coronary 
intervention (PCI). The inclusion criteria were as follows: 
diagnosis of a first STEMI or CCS (both groups referred 
for PCI), glomerular filtration rate (GFR) of 60 mL/min or 
higher and left ventricular ejection fraction (LVEF) of 50% or 
higher on echocardiography at hospital admission. Patients 
with a GFR of less than 60 mL/min, myocardial infarction 
at previously, LVEF lower than 50% on admission, severe 
valvular calcification, current treatment with vitamin K anta-
gonists, disorders of calcium and phosphorus metabolism, 
autoimmune disorders, acute infection on admission, and 
current malignancies were excluded.
The Thrombolysis in Myocardial Infarction (TIMI) Risk 
Score (STEMI) was used for estimation of 30-day mortali-
ty in patients with STEMI [8]. After hospital discharge pa-
tients with STEMI underwent 30 days follow-up. During this 
time, participants were contacted by phone and 30 days 
after infarction the patients were assessed at the outpa-
tients’ department.
The primary endpoint was the occurrence of a differen-
ce in ucMGP concentration between STEMI patients when 
compared to CCS. Secondary endpoints were the relation-
ship between levels of ucMGP in STEMI and a combination 
of MACE including all-cause mortality and heart failure (HF) 
within the first 30 days after MI.
Laboratory measurements
Serum concentrations of ucMGP were measured with 
a sandwich enzyme-linked immunosorbent assay, double 
antibody kit (MyBioSource, Inc., San Diego, California, 
United States), with a detection range of 0.156 to 10 ng/mL, 
a sensitivity of 0.094 ng/mL, and intra- and interassay coef-
ficients of variation of less than 8% and 10%, respectively. 
Blood samples were obtained within 24 hours from hospital 
admission, after the PCI procedure.
Other laboratory examinations included complete blood 
count, renal function tests, lipids profile, and the measu-
rement of high-sensitive C-reactive protein (hsCRP) levels 
were measured in patients with STEMI.
Complete echocardiography was performed using the 
VIVID S-6 ECHO unit (GE Medical System), equipped with 
a multifrequency harmonic transducer (2.5–4 MHz) before 
hospital discharge and at the end of follow-up. The systolic 
Introduction
Matrix Gla proteins (MGPs) are extrahepatic vitamin 
K-dependent proteins produced not only by chondrocytes 
and fibroblasts but also by vascular smooth muscle cells in 
the arterial media and other tissues such as some cancer 
cells [1–3]. The biological function of MGPs remains the 
subject of research, the proteins are usually perceived 
as natural inhibitors of the arterial wall and soft tissue 
calcification [1–3]. They protect tissues against calcifica-
tion by binding newly formed hydroxyapatite crystals (and 
thereby preventing their accumulation in tissues) as well 
as by stimulation of vascular macrophages to promote 
phagocytosis and apoptosis of the MGP-hydroxyapatite 
complexes [2–6]. MGPs also inhibit the binding of bone 
morphogenetic protein 2 (BMP-2) to its receptor, which 
impairs protein function. Expression of BMP-2 in endo-
thelial foam cells of atherosclerotic plaques leads to 
chondrogenesis and osteogenesis, and thus to vascular 
calcification [5].
For biological activation, MGPs have to undergo car-
boxylation of the Gla residues, followed by phosphoryla-
tion of the serine residues. Both carboxylation and phos-
phorylation depend on vitamin K2 (especially menaquino-
ne 7). Only the active form of MGP is both phosphorylated 
and carboxylated, while uncarboxylated MGP (ucMGP) and 
carboxylated but not phosphorylated MGP, as well as pho-
sphorylated but uncarboxylated MGP, are partially active 
forms. Finally, uncarboxylated and dephosphorylated MGP 
is a fully inactive form [3].
The biological role of different forms of MGPs as mar-
kers of cardiovascular disease remains controversial. Se-
rum ucMGP concentrations were reported to correlate with 
arterial calcification in patients with hypertension [3]. Low 
plasma ucMGP levels were independently associated with 
mortality and cardiovascular complications in patients with 
coronary artery disease [4]. High plasma levels of carboxy-
lated but not phosphorylated MGP were independently as-
sociated with mortality in patients with chronic cardiova-
scular disorders [1, 6, 7].
Although previous studies have confirmed a positive 
association between elevated circulating serum levels 
of MGPs in cardiovascular disorders related to chronic 
inflammation, there are limited data on MGP levels in 
inflammatory states related to acute ischemia. Therefo-
re, the present study aimed to evaluate serum ucMGP 
levels in patients with ST-segment elevation myocardial 
infarction (STEMI) compare to those with chronic corona-
ry syndromes (CCS) and also to investigate the associa-
tion between serum ucMGP concentration and an incre-
ased risk of major adverse cardiovascular events (MACE) 
in STEMI patients.
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function of the left ventricle was estimated with LVEF using 
the Simpson method. The average values of three conse-
cutive measurements were recorded.
Important definitions
STEMI was defined by electrocardiographic ST-segment 
elevation in patients with chest discomfort/pain or equiva-
lent) with positive biomarkers of necrosis [troponin T or/and 
creatine kinase myocardial band (CK-MB)]. Hypertension 
was defined as arterial blood pressure equal to or more 
than 140/90 mm Hg or drugs treatment for hypertension. 
CCS was defined as typical angina induced by exertion or 
emotional stress with positive results of treadmill exercise 
stress or stress echocardiography, perfusion scintigraphy. 
Hyperlipidaemia was defined as low-density lipoprotein 
(LDL)-cholesterol ≥ 1,7 mmol/L or/and elevation triglyce-
rides ≥ 1,7 mmol/L or treatment with hypolipemic therapy/ 
/diet. Diabetes mellitus was diagnosed in line with appli-
cable guidelines [9].
The study protocol complied with the Declaration of 
Helsinki and was approved by the Ethics Committee of Ja-
giellonian University (KBET; 122.6120.323.2014). Each 
study participant provided written informed consent be-
fore enrolment.
Statistical analysis
All continuous variables were expressed as mean [standard 
deviation (SD)], and categorical variables were expressed 
as percentages. The Mann–Whitney test was used to com-
pare normally and non-normally distributed continuous 
variables. The analysis of variance or the Kruskal–Wallis 
test was applied as appropriate. The χ2 test was used to 
evaluate the differences in categorical variables between 
study groups. All statistical tests were 2-sided. The relation-
ships between continuous variables were assessed by the 
Spearman rank correlation. A multiple regression analysis 
was used for identifying associates of STEMI and with MACE 
as a dependent variable. Statistical significance was ac-
cepted at a p-value of less than 0.05. Statistical analysis 
was performed using the STATISTICA 13.0 PL software 
(StatSoft, Poland).
Results
A clinical characteristic of study patients has been provided 
in Table 1.
A total of 155 participants aged 48 to 76 years [mean 
standard deviation (SD) age, 64 (13) years; men, 72%] 
were enrolled. The mean ± SD TIMI risk score in the STEMI 
patients with STEMI were 3.68 ± 2.67. The baseline char-
acteristics of the study population have been presented 
in Table 1.
Serum levels of ucMGP were higher in patients with 
STEMI than in those with CCS (2929 ± 96.5 ng/mL; range, 
689–16,310 ng/mL vs. 67.3 ± 32.3 ng/mL; range, 19.1– 
–520.3 ng/mL, p < 0.0001). There were no differences in 
ucMGP levels between patients with single-vessel and those 
with the multivessel disease either in the STEMI or controls.
In patients with STEMI, ucMGP levels correlated with 
peak troponin (r = 0.35, p = 0.03), peak CK-MBmass (r = 0.41, 
p = 0.02), and hsCRP levels (r = 0.34, p < 0.001), as well 
as with LVEF (r = –0.37, p = 0.01). There was no correla-
tion between ucMGP levels and the levels of low-density 
lipoprotein cholesterol, triglycerides, high-density lipopro-
tein cholesterol, haemoglobin, and fasting glucose in either 
group. In patients with CCS, ucMGP levels correlated only 
with hsCRP levels (r = 0.42, p = 0.04). In both STEMI and 
controls the levels of ucMGP were higher in patients with 
diabetes compare to non-diabetic ones (STEMI: p = 0.03; 
controls: p = 0.04; respectively).
In multivariate analysis ucMGP, hsCRP concentrations, 
hypertension, diabetes, age, waist circumference were 
independent associates of STEMI (Table 2). During the 
post-infarction follow-up, 3 deaths occurred, 10 patients 
revealed HF. Thus, combined MACE was observed in the 
6.25% STEMI patients.
When the participants were compared concerning the 
occurrence of MACE within the first month after the STEMI, 
the ucMGP of 2832 + 92.2 ng/mL was observed in the 
group presenting with the endpoint and 2794 ± 89.7 in the 
remaining (p = 0.05). Among those who developed HF, the 
ucMGP was 2937 ± 92.4 ng/mL, while in patients without 
HF the ucMGP was 2889 ± 87.2 ng/mL in the group with-
out HF (p = 0.03). When ucMGP was assessed in relation 
to death, there was no significant association (p = 0.07). 
Multivariate analysis of ucMGP in relation to HF, after ad-
justing the confounders: age below 40 years or equal and 
above 75 years old at admission, sex, diabetes mellitus, 
LVEF bellow 50% at hospital discharge, anterior ST eleva-
tion, time to primary PCI treatment above 4 hours showed 
an OR of 1.20 (95% CI: 1.07–1.30, p = 0.04).
Discussion
To the authors’ knowledge, this is the first study that not 
only compares ucMGP concentrations between patients 
with STEMI and those with CCS but also assesses the re-
lationship between levels of ucMGP in the acute phase of 
STEMI and combination of MACE including all-cause mor-
tality, HF within the first 30 days after MI. Higher serum uc-
MGP levels in patients with STEMI than in controls, as well 
as the significant positive correlation between ucMGP and 
CR, troponin and CK-MB levels in these patients, suggests 
that some MGPs may be involved in acute inflammation 
87www.journals.viamedica.pl/folia_cardiologica
Ewa Konduracka et al., Matrix Gla protein in patients with myocardial infarction
related to the size of myocardial necrosis, plaque rupture 
and thrombosis in the course of acute myocardial ischemia.
We hypothesized that MGP secretion may be stimula-
ted by inflammatory cytokines, cell adhesion molecules, 
and acute-phase proteins, which are released in STEMI. 
In an experimental animal study, Yao et al. [10] demon-
strated that MGP was bound by serum-soluble heat shock 
protein 70 (HSP-70), which is also released in myocardial 
infarction and expressed in atherosclerotic lesions. This 
may result in elevation of the plasma levels of the partially 
active form, namely, ucMGP. In human studies, elevated 
HSP-70 levels correlated with ischemic myocardial damage 
[11]. In the presented study, the size of infarct (evaluated 
based on troponin and CK-MB levels as well as LVEF) po-
sitively correlated with CRP levels as a marker of an acu-
te inflammatory reaction. The CRP synthesis is influenced 
by interleukin 6, which enhances vascular calcification in 
vitro [12], an action that is opposite to the function of the 
active MGP form. The activation of MGP may play a multifa-
ceted protective role in artery integrity also in acute injury.






Male sex, N [%] 62 (76) 50 (67) 0.13
Age, years 58.34 (11.33) 53.23 (10.57) 0.09
Hypertension, N [%] 75 (94) 68 (91) 0.47
Diabetes mellitus, N [%] 34 (42) 42 (56) 0.09
BMI [kg/m2] 25.3 (4.45) 25.9 (3.98) 0.06
Waist circumference [cm] 97.4 (4.67) 94.7 (4.85) 0.07
Smoking, N [%] 14 (18) 10 (13) 0.47
LVEF [%] 54.21 (3.41) 64.32 (4.33) 0.002
Coronary angiography, N [%]
Single-vessel disease
Two-vessel disease










LDL-C [mmol/L] (SD)* 2.60 (0.42) 2.82 (0.2) 0.09
Triglycerides [mmol/L] (SD)* 1.31 (0.5) 1.23 (0.3) 0.06
HDL-C [mmol/L] (SD)* 1.13 (0.73) 1.24 (0.5) 0.08
Haemoglobin [g/dL] (SD)* 14.51 (0.78) 14.32 (1.3) 0.65
hsCRP [mg/dL] (SD)* 16.41 (4.21) 2.73 (1.24) < 0.0001
eGFR [mL/min] (SD)* 81 (13.52) 78 (12.51) 0.56
Baseline CK-MB [U/l] (SD)* 23.51 (3.45) – –
Peak CK-MB [U/l] (SD)* 45.52 (2.73) – –
Baseline hsTnT [ng/mL] (SD)* 0.76 (0.45)
Peak hsTnT [ng/mL] 6.56 (1.34) – –
Treatment on admission, N [%]
ACEI 60 (75) 54 (72) 0.67
ARB 7 (9) 9 (12) 0.50
Beta-adrenolytics 37 (46) 45 (60) 0.08
CCB 17 (21) 24 (32) 0.12
Diuretics 15 (19) 25 (33) 0.03
Antiplatelet agents 80 (100) 75 (100) 1.00
Statins therapy 39 (49) 48 (64) 0.05
*Data are shown as mean ± standard deviation (SD); STEMI — ST-segment elevation myocardial infarction; CCS — chronic coronary syndromes; BMI — body mass index; LVEF — left ventricular ejection 
fraction; LDL-C — low-density lipoprotein cholesterol; HDL-C — high-density lipoprotein cholesterol; eGFR — estimated glomerular filtration rate (CKD-EPI formula); hsCRP — high-sensitivity C-reactive protein; 
CK-MB — creatine kinase-myocardial band; hsTnT — high-sensitivity troponin T; ACEI — angiotensin-converting enzyme inhibitor; ARB — angiotensin receptor blocker; CCB — channel calcium blocker
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Dahlberg et al. [13] observed increased concentrations 
of dp-ucMGP in surgical patients in the early postoperative 
period, and the expression of this protein was particularly 
high in patients at cardiovascular risk. The authors postu-
lated poor levels of vascular vitamin K in those patients 
and suggested next research about interactions between 
perioperative corrective treatment with different types of 
vitamin K supplements and cardiovascular complications. 
Meanwhile, human studies on changes in ucMGP levels in 
patients with myocardial infarction are very limited. In con-
trast to the presented results, Margonato et al. [14] did 
not reveal any differences in the serum concentrations of 
MGP between patients with STEMI and CCS; however, in 
the presented and their studies MGP concentrations were 
higher in patients with diabetes compared with nondia-
betic individuals.
In another study, Buyukterzi et al. [15] compared pa-
tients with acute coronary syndromes (ACS) and those with 
normal coronary arteries on angiography. The levels of uc-
MGP were significantly higher in patients with ACS than in 
those with normal epicardial coronary arteries. Similar to 
this study, the ucMGP concentrations correlated with CRP 
levels and LVEF, but in contrast to this study findings, the 
authors did not report the association of ucMGP with tro-
ponin and CK-MB levels. Is possible that those differences 
between studies arise from the larger size of MI and se-
condary higher values of troponin, CK-MB levels in the 
presented study (included only STEMI patients) compare 
to previously published work (included also patients with 
unstable angina, non -STEMI and STEMI).
Although in the presented work ucMGP levels (in addi-
tion to ageing, diabetes, hypertension, abdominal obesity 
and hsCRP levels) were independent associates of STEMI 
however ucMGP was not predictive of combined MACE wit-
hin 30 days after STEMI treated with primary PCI. On the 
other hand, it has been demonstrated that ucMGP was 
significantly higher in patients who developed HF within 
30 days of the STEMI. The association remained also after 
adjustment for age, sex diabetes, LVEF (at discharge), an-
terior ST elevation, time to primary PCI treatment. Results 
suggest the potential role of matrix Gla proteins as a mar-
ker of HF development in short term follow-up after STEMI.
The available studies have assessed the mechanism of 
MGP expression only in disorders associated with chronic 
low-grade systemic inflammation. Although the presented 
study does not elucidate the role or the mechanism of MGP 
expression in acute MI, elevated MPG levels in patients with 
STEMI and its predictive value in STEMI and HF in short 
term follow-up indicate the need for further research on 
the biological function of MGPs.
Table 2. Univariate and multivariate regression analysis for identifying associates of ST-segment elevation myocardial infarction
Variables OR 95% CI p-value
Univariate analysis
Male sex 1.5 0.30–4.05 0.02
Age (years) 3.02 0.56–4.9 0.003
Hypertension 3.09 1.0–5.20 < 0.0001
Diabetes mellitus 2.15 0.52–3.83 0.001
BMI [kg/m2] 1.45 0.42–3.39 0.01
Waist circumference [cm] 1.98 1.02–3.78 0.03
ucMGP [ng/mL] 1.92 1.15–3.15 0.001
hsCRP [ng/mL] 3.45 1.23–3.46 < 0.00001
LDL-C [mmol/L] 1.15 1.02–2.90 0.09
Triglycerides [mmol/L] 1.27 0.89–1.98 0.53
HDL-C [mmol/L] 0.92 0.34–1.72 0.39
Multivariate analysis
Age (years) 1.47 0.78–5.15 < 0.0001
Waist circumference > 100 cm 1.54 0.72–2.32 0.04
Hypertension 2.45 0.78–4.78 < 0.0001
Diabetes 2.32 1.01–3.98 0.002
hsCRP [mg/dL] 1.45 0.81–2.78 0.02
ucMGP [ng/mL] 1.39 0.78–2.14 0.01
OR — odds ratio; CI — confidence interval; BMI — body mass index; ucMGP — uncarboxylated matrix Gla proteins; hsCRP — high-sensitivity C-reactive protein; LDL-C — low-density lipoprotein cholesterol;  
HDL-C — high-density lipoprotein cholesterol
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Streszczenie
Wprowadzenie. Białka macierzy Gla (MGP) uważa się za naturalne inhibitory wapnienia tkanek miękkich w przewlekłych sta-
nach zapalnych. Jednak stężenie MGP w ostrym procesie zapalnym towarzyszącym zawałowi serca zostało słabo zbadane.
Celem tego badania było porównanie stężeń niedokarboksylowanego MGP (ucMGP) w surowicy u pacjentów z zawałem 
serca z uniesieniem odcinka ST (STEMI) ze stężeniami ucMGP u osób z przewlekłymi zespołami wieńcowymi (CCS) oraz 
zbadanie związku między stężeniem ucMGP a podwyższonym ryzykiem poważnych niepożądanych zdarzeń sercowo-
-naczyniowych (MACE) u pacjentów ze STEMI.
Materiał i metody. Do badania włączono 155 kolejnych pacjentów (średnio ± odchylenie standardowe 64 ± 13 lat), 
w tym 80 pacjentów ze STEMI jako pierwszą manifestacją choroby wieńcowej oraz 75 pacjentów z CCS jako grupą 
kontrolną. Próbki krwi pobrano w pierwszych 24 h od przyjęcia do szpitala w celu oceny stężenia ucMGP. Oceniono MACE 
złożony ze śmiertelności ogólnej oraz niewydolności serca (HF) w pierwszych 30 dniach po zawale serca.
Wyniki. Stężenie ucMGP były istotnie wyższe u pacjentów ze STEMI niż w grupie kontrolnej (2929 ± 96,5 ng/ml vs. 67,3 
± 32,3 ng/ml; p < 0,0001). Stwierdzono istotną dodatnią korelację między ucMGP, białkiem C-reaktywnym oznaczanym 
metodą wysokoczułą oraz stężeniem troponiny sercowej. Analiza wieloczynnikowa wykazała, że ucMGP był niezależnie 
związany z wystąpieniem STEMI (iloraz szans [OR] 1,39; przedział ufności [CI]: 0,78–2,14; p = 0,01). Jednakże stężenie 
ucMGP nie było predyktorem złożonego MACE, ale wiązało się niezależnie z wystąpieniem HF 30 dni po STEMI (OR, 
1,20; 95% CI: 1,07–1,30; p = 0,04).
Wnioski. Podwyższone stężenie ucMGP u pacjentów ze STEMI wskazuje, że niektóre MGP mogą uczestniczyć także 
w ostrych stanach zapalnych.
Słowa kluczowe: niedokarboksylowane białko macierzy Gla, zawał serca, przewlekły zespół wieńcowy
Folia Cardiologica 2021; 16, 2: 84–90
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